# Kymera Therapeutics > biopharmaceutical company **Wikidata**: [Q113503520](https://www.wikidata.org/wiki/Q113503520) **Source**: https://4ort.xyz/entity/kymera-therapeutics ## Summary Kymera Therapeutics is a publicly traded biopharmaceutical company focused on developing targeted protein degradation therapies. As a public company, it offers its securities (stock) for sale to the general public via the Nasdaq stock exchange under the ticker symbol KYMR. Kymera specializes in advancing novel treatments for diseases with high unmet medical needs, particularly in oncology and autoimmune disorders. ## Key Facts - **Legal Classification**: Public company (instance_of: public company) - **Industry**: Pharmaceutical industry - **Headquarters**: Watertown, Massachusetts, USA - **Stock Exchange Listing**: Nasdaq (ticker symbol: KYMR, since August 21, 2020) - **Central Index Key (CIK)**: 0001815442 (U.S. Securities and Exchange Commission identifier) - **International Securities Identification Number (ISIN)**: US5015751044 - **Website**: [https://www.kymeratx.com/](https://www.kymeratx.com/) (English-language) - **Crunchbase Organization ID**: kymera-therapeutics - **Wikidata Description**: Biopharmaceutical company - **Primary Focus**: Development of heterobifunctional degraders and molecular glue degraders for targeted protein degradation therapies - **Therapeutic Areas**: Oncology, autoimmune diseases, and other conditions with unmet medical needs ## FAQs **What is Kymera Therapeutics?** Kymera Therapeutics is a biopharmaceutical company that develops targeted protein degradation therapies, a novel approach to treating diseases by selectively breaking down disease-causing proteins. It is a public company, meaning its shares are traded on the Nasdaq stock exchange. **How is Kymera Therapeutics classified?** Kymera Therapeutics is classified as a public company, a type of joint-stock company that offers its securities to the general public. It operates in the pharmaceutical industry and is headquartered in Watertown, Massachusetts. **What is Kymera Therapeutics’ stock ticker and when did it go public?** Kymera Therapeutics trades on the Nasdaq stock exchange under the ticker symbol KYMR. The company went public on August 21, 2020. **What types of therapies does Kymera Therapeutics develop?** Kymera Therapeutics specializes in targeted protein degradation therapies, including heterobifunctional degraders and molecular glue degraders. These therapies aim to eliminate disease-causing proteins rather than merely inhibiting their function. **Where can I find official information about Kymera Therapeutics?** Official information about Kymera Therapeutics can be found on its website ([https://www.kymeratx.com/](https://www.kymeratx.com/)) and through regulatory filings with the U.S. Securities and Exchange Commission (SEC), identified by its Central Index Key (CIK) 0001815442. **What distinguishes Kymera Therapeutics from other biopharmaceutical companies?** Kymera Therapeutics distinguishes itself through its focus on targeted protein degradation, a cutting-edge approach in drug development. Unlike traditional pharmaceutical companies that develop inhibitors, Kymera’s therapies are designed to degrade proteins linked to disease, offering potential for treating conditions that lack effective therapies. **Is Kymera Therapeutics a government-owned entity?** No, Kymera Therapeutics is not a government-owned entity. It is a publicly traded, privately managed biopharmaceutical company owned by its shareholders. ## Why It Matters Kymera Therapeutics plays a critical role in advancing the field of targeted protein degradation, a transformative approach in drug development. By focusing on degrading disease-causing proteins rather than merely inhibiting them, Kymera’s therapies have the potential to address diseases with high unmet medical needs, such as certain cancers and autoimmune disorders. As a public company, Kymera provides investors with an opportunity to participate in the growth of a biopharmaceutical innovator while contributing to the development of next-generation treatments. Its work bridges the gap between scientific discovery and clinical application, offering hope for patients who lack effective therapeutic options. ## Notable For - **Pioneering Targeted Protein Degradation**: Kymera Therapeutics is at the forefront of developing heterobifunctional degraders and molecular glue degraders, a novel class of therapies with broad potential across multiple disease areas. - **Publicly Traded Biopharmaceutical Company**: As a Nasdaq-listed company (KYMR), Kymera provides transparency and liquidity to investors while adhering to regulatory standards for public companies. - **Focus on Unmet Medical Needs**: The company’s pipeline targets diseases with limited or no effective treatments, including oncology and autoimmune disorders. - **Strong Scientific Foundation**: Kymera’s research is grounded in the emerging field of targeted protein degradation, which has garnered significant attention from the scientific and medical communities. - **Regulatory Compliance**: As a public company, Kymera adheres to strict disclosure and reporting requirements, ensuring transparency for investors and stakeholders. ## Body ### Overview and Mission Kymera Therapeutics is a biopharmaceutical company dedicated to discovering and developing targeted protein degradation therapies. Its mission is to transform the treatment of diseases by leveraging the body’s natural protein degradation machinery to eliminate disease-causing proteins. This approach differs from traditional drug development, which often focuses on inhibiting protein function rather than removing the protein entirely. ### Legal and Corporate Structure - **Public Company Status**: Kymera Therapeutics is classified as a public company, meaning its shares are available for purchase by the general public on the Nasdaq stock exchange. This structure allows the company to raise capital from a broad investor base while complying with regulatory requirements for transparency and disclosure. - **Headquarters**: The company is headquartered in Watertown, Massachusetts, a hub for biotechnology and pharmaceutical innovation. - **Stock Exchange and Ticker Symbol**: Kymera’s shares trade on the Nasdaq under the ticker symbol KYMR, with its initial public offering (IPO) occurring on August 21, 2020. ### Industry and Therapeutic Focus - **Pharmaceutical Industry**: Kymera operates within the pharmaceutical industry, specifically focusing on the development of targeted protein degradation therapies. - **Targeted Protein Degradation**: The company’s scientific platform centers on heterobifunctional degraders and molecular glue degraders, which are designed to recruit the cell’s ubiquitin-proteasome system to degrade specific proteins linked to disease. - **Therapeutic Areas**: Kymera’s pipeline primarily targets oncology and autoimmune diseases, where protein degradation may offer advantages over traditional therapeutic approaches. ### Financial and Regulatory Identifiers - **ISIN**: Kymera’s International Securities Identification Number (ISIN) is US5015751044, a unique identifier for its publicly traded securities. - **Central Index Key (CIK)**: The company’s CIK is 0001815442, a unique identifier assigned by the U.S. Securities and Exchange Commission (SEC) for regulatory filings. - **Crunchbase ID**: Kymera is listed on Crunchbase under the identifier kymera-therapeutics, a platform tracking information about companies and startups. ### Online Presence and Resources - **Official Website**: Kymera’s website ([https://www.kymeratx.com/](https://www.kymeratx.com/)) provides detailed information about its pipeline, scientific approach, leadership team, and investor relations. The website is available in English. - **Wikidata Entry**: Kymera Therapeutics is described in Wikidata as a biopharmaceutical company, reflecting its focus on drug development and commercialization. ### Scientific and Clinical Approach - **Heterobifunctional Degraders**: Kymera’s heterobifunctional degraders consist of two linked molecules: one that binds to a disease-causing protein and another that recruits the cell’s degradation machinery. This approach enables the selective degradation of target proteins. - **Molecular Glue Degraders**: These small molecules induce proximity between a target protein and an E3 ubiquitin ligase, leading to the ubiquitination and degradation of the target protein. Molecular glue degraders are a promising class of therapies with potential applications across multiple diseases. - **Pipeline**: Kymera’s pipeline includes candidates in preclinical and clinical stages, with a focus on validating the safety and efficacy of its targeted protein degradation therapies. ### Investor and Shareholder Information - **Public Ownership**: As a public company, Kymera’s ownership is distributed among its shareholders, who can buy and sell shares on the Nasdaq stock exchange. This structure provides liquidity and access to capital for the company’s growth and development. - **Investor Relations**: Kymera provides investor relations resources, including financial reports, corporate presentations, and updates on clinical progress, to keep shareholders and the public informed about its business and pipeline. ### Distinction from Similar Entities - **Not a Public Enterprise**: Kymera Therapeutics is distinct from public enterprises or government-owned entities, which are typically state-run organizations. Instead, it is a privately managed, publicly traded company. - **Focus on Innovation**: Unlike traditional pharmaceutical companies that develop small-molecule inhibitors or biologics, Kymera’s focus on targeted protein degradation represents a novel and potentially disruptive approach to drug development. - **Regulatory Environment**: As a public company, Kymera adheres to stringent regulatory requirements, including financial disclosures, corporate governance standards, and clinical trial regulations, ensuring transparency and accountability.